TrialPath
Recruiting

A Study of AZD0120 in Autoimmune Diseases

NCT07295847 · AstraZeneca
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1b/2, Open-label, Multi-cohort Study of AZD0120, an Autologous CD19/BCMA Targeting Chimeric Antigen Receptor T-cell, in Adults With Autoimmune Diseases
About this study
This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).
Eligibility criteria
Inclusion Criteria: * Capable of giving signed informed consent. * Adequate physiological function and reserve at screening. * Able to comply with recommended medication washout period. * Participants who are suitable for the study as determined by medical evaluation and at the discretion of the investigator. * Willingness to remain on/start appropriate, highly effective methods of birth control or other acceptable criteria. * Particpant musy be 18-years-old to ≤ 75-years-old inclusive at the time of signing the informed consent * Others as described in Clinical Study Protocol Exclusion Criteria: * Any prior CAR T exposure. * Unable or unwilling to remain within proximity (2 hours travel time) of the administering investigational site post discharge for the first 28 days post AZD0120 administration. * Received a bone marrow or solid organ transplant at any time or on an active transplant waiting list. * Received any investigational drug within ≥ 5 half-lives or 4 weeks, whichever is longer, prior to screening. * Has certain cardiac conditions that could make it unsafe or unsuitable to take part in the study. * Requirement for supplemental oxygen at rest (except at night for sleep apnea) or mechanical ventilation. * Uncontrolled hypertension (\> 160/100 mmHg) or symptomatic hypertension. * Any central nervous system disease that may impact participants safety in the investigator's opinion. * Other concurrent autoimmune or autoinflammatory disease. Certain autoimmune/autoinflammatory diseases may be included after discussion with the medical monitor. * Evidence of clinically significant bleeding or active bleeding conditions within 90 days before screening * History of malignancy or ongoing treatment for prior malignancy. Certain malignancies may be excepted. * Known genetic inborn error of immunity and/or primary immunodeficiency. * Active viral, bacterial, or fungal infection, or any ongoing infection that requires systemic antimicrobial therapy in the 4 weeks prior to screening. * Seropositive for HIV or HTLV. * Active viral hepatitis are excluded. * Active syphilis, positive for Treponema pallidum antibody. * Vaccinated with live, attenuated vaccine within 4 weeks prior to apheresis or lymphodepletion. * Not up-to-date on vaccinations per local/national health authority or institutional guidelines for immune-compromised individuals. * Known life threatening allergies, hypersensitivity, or intolerance to AZD0120 or its excipients, including dimethyl sulfoxide. * Contraindications or hypersensitivity to fludarabine and cyclophosphamide. * \- Major surgery within 8 weeks prior to apheresis or has surgery planned during the study. * Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment (whichever is later). * Plans to father a child while enrolled in this study or within 1 year after receiving study treatment (whichever is later). * Any issue that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site, to provide informed consent or any condition in the opinion of the investigator, participation would not be in the best interest of the participant. * Other protocol-defined eligibility criteria may apply.
Study design
Enrollment target: 27 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-01-09
Estimated completion: 2028-02-22
Last updated: 2026-11-10
Interventions
Biological: AZD0120Drug: SOC
Primary outcomes
  • • Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) (1 year)
  • • Proportion of Participants Achieving a Revised-CRISS Response (Baseline, Week 52)
  • • Proportion of participants achieving TIS response and low corticosteroid dose (Baseline, Week 52)
Sponsor
AstraZeneca · industry
Contacts & investigators
ContactAstraZeneca Clinical Study Information Center · contact · information.center@astrazeneca.com · 1-877-240-9479
All locations (27)
Research SiteNot Yet Recruiting
Tucson, Arizona, United States
Research SiteNot Yet Recruiting
Duarte, California, United States
Research SiteNot Yet Recruiting
Stanford, California, United States
Research SiteNot Yet Recruiting
Miami, Florida, United States
Research SiteNot Yet Recruiting
Chicago, Illinois, United States
Research SiteNot Yet Recruiting
Baltimore, Maryland, United States
Research SiteRecruiting
Ann Arbor, Michigan, United States
Research SiteNot Yet Recruiting
St Louis, Missouri, United States
Research SiteNot Yet Recruiting
New York, New York, United States
Research SiteRecruiting
New York, New York, United States
Research SiteRecruiting
Chapel Hill, North Carolina, United States
Research SiteNot Yet Recruiting
Seattle, Washington, United States
Research SiteNot Yet Recruiting
Clayton, Australia
Research SiteRecruiting
Darlinghurst, Australia
Research SiteNot Yet Recruiting
Waratah, Australia
Research SiteNot Yet Recruiting
Berlin, Germany
Research SiteNot Yet Recruiting
Erlangen, Germany
Research SiteNot Yet Recruiting
Hamburg, Germany
Research SiteNot Yet Recruiting
Jena, Germany
Research SiteNot Yet Recruiting
Mainz, Germany
Research SiteNot Yet Recruiting
Würzburg, Germany
Research SiteNot Yet Recruiting
Barcelona, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Madrid, Spain
Research SiteNot Yet Recruiting
Huddinge, Sweden
Research SiteRecruiting
Edinburgh, United Kingdom
Research SiteNot Yet Recruiting
London, United Kingdom
A Study of AZD0120 in Autoimmune Diseases · TrialPath